Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer

Clinical Cancer Research, 02/23/2012

Dual VEGF/epidermal growth factor receptor (EGFR)R inhibition can be integrated with chemoradiation (CRT) in locally advanced head and neck cancer (HNC), with efficacy that compares favorably with historical controls albeit with an increased risk of osteoradionecrosis. Pretreatment and early DCE–MRI may prospectively identify patients at high risk of failure.

Print Article Summary Cat 2 CME Report